The antioxidant paradox: What are antioxidants and how should they be used in a therapeutic context for cancer

Future Medicinal Chemistry

Volumn 6, Issue 12, 2014, Pages 1413-1422

  Bonner, Michael Y ^a,b   Arbiser, Jack L ^a,b  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROTEIN P53; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; THIOL DERIVATIVE; TOCOPHEROL;

DRUG MECHANISM; HUMAN; INFLAMMATION; NEOPLASM; RECOGNITION; REVIEW; TUMOR CELL; TUMOR REGRESSION; WILD TYPE; CHEMISTRY; NEOPLASMS; PATHOLOGY;

ANTIOXIDANTS; HUMANS; NEOPLASMS;

EID: 84908135486     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/FMC.14.86     Document Type: Review

References (75)

1. Talalay P, Batzinger RP, Benson AM, Bueding E, Cha YN. Biochemical studies on the mechanisms by which dietary antioxidants suppress mutagenic activity. Adv. Enzyme Regul. 17, 23-36 (1978).
2. Fahey JW, Talalay P. Antioxidant functions of sulforaphane: a potent inducer of Phase II detoxication enzymes. Food Chem. Toxicol. 37(9-10), 973-979 (1999).
3. Cotter MA, Thomas J, Cassidy P et al. N-acetylcysteine protects melanocytes against oxidative stress/damage and delays onset of ultraviolet-induced melanoma in mice. Clin. Cancer Res. 13(19), 5952-5958 (2007).
4. Peebles DD, Soref CM, Copp RR, Thunberg AL, Fahl WE. ROS-scavenger and radioprotective efficacy of the new PrC-210 aminothiol. Radiat. Res. 178(1), 57-68 (2012).
5. Velu CS, Niture SK, Doneanu CE, Pattabiraman N, Srivenugopal K S. Human p53 is inhibited by glutathionylation of cysteines present in the proximal DNA-binding domain during oxidative stress. Biochemistry 46(26), 7765-7780 (2007).
6. Yusuf MA, Chuang T, Bhat GJ, Srivenugopal K S. Cys-141 glutathionylation of human p53: studies using specific polyclonal antibodies in cancer samples and cell lines. Free Radic. Biol. Med. 49(5), 908-917 (2010).
7. Shen Y, Zhong L, Markwell S, Cao D. Thiol-disulfide exchanges modulate aldo-keto reductase family 1 member B10 activity and sensitivity to inhibitors. Biochimie 92(5), 530-537 (2010).
8. Agar N, Young AR. Melanogenesis: a photoprotective response to DNA damage? Mutat. Res. 571(1-2), 121-132 (2005).
9. Gao P, Zhang H, Dinavahi R et al. HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell 12(3), 230-238 (2007).
10. Nayak BK, Feliers D, Sudarshan S et al. Stabilization of HIF-2alpha through redox regulation of mTORC2 activation and initiation of mRNA translation. Oncogene 32(26), 3147-3155 (2013).
11. Estrela JM, Ortega A, Obrador E. Glutathione in cancer biology and therapy. Crit. Rev. Clin. Lab. Sci. 43(2), 143-181 (2006).
12. Jiang T, Chen N, Zhao F et al. High levels of Nrf2 determine chemoresistance in type II endometrial cancer. Cancer Res. 70(13), 5486-5496 (2010).
13. Kensler TW, Davidson NE, Groopman JD, Roebuck BD, Prochaska HJ, Talalay P. Chemoprotection by inducers of electrophile detoxication enzymes. Basic Life Sci. 61, 127-136 (1993).
14. Kensler TW, Wakabayashi N, Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu. Rev. Pharmacol. Toxicol. 47, 89-116 (2007). •• Extensive review of the physiological role of the Keap-Nrf2 pathway.
15. Tertil M, Skrzypek K, Florczyk U et al. Regulation and novel action of thymidine phosphorylase in non-small cell lung cancer: crosstalk with Nrf2 and HO-1. PLoS ONE 9(5), e97070 (2014).
16. Bello RI, Kagan VE, Tyurin V, Navarro F, Alcain FJ, Villalba JM. Regeneration of lipophilic antioxidants by NAD(P) H:quinone oxidoreductase 1. Protoplasma 221(1-2), 129-135 (2003).
17. Xu MJ, Plezia PM, Alberts DS et al. Reduction in plasma or skin alpha-tocopherol concentration with long-term oral administration of beta-carotene in humans and mice. J. Natl Cancer Inst. 84(20), 1559-1565 (1992).
18. Lamontagne KR Jr, Moses MA, Wiederschain D et al. Inhibition of MAP kinase kinase causes morphological reversion and dissociation between soft agar growth and in vivo tumorigenesis in angiosarcoma cells. Am. J. Pathol. 157(6), 1937-1945 (2000).
19. Govindarajan B, Klafter R, Miller MS et al. Reactive oxygen-induced carcinogenesis causes hypermethylation of p16(Ink4a) and activation of MAP kinase. Mol. Med. 8(1), 1-8 (2002).
20. Arbiser JL, Mann KP, Losken EM et al. Presence of p16 hypermethylation and Epstein-Barr virus infection in transplant-associated hematolymphoid neoplasm of the skin. J. Am. Acad. Dermatol. 55(5), 794-798 (2006).
21. Cerimele F, Battle T, Lynch R et al. Reactive oxygen signaling and MAPK activation distinguish Epstein-Barr Virus (EBV)-positive versus EBV-negative Burkitt's lymphoma. Proc. Natl Acad. Sci. USA 102(1), 175-179 (2005). •• First paper to identify Epstein-Barr virus as an oxidative carcinogen and to demonstrate the inverse relationship between reactive oxygen and MAPK signaling in a cancer cell.
22. Bonner MY, Arbiser JL. Targeting NADPH oxidases for the treatment of cancer and inflammation. Cell Mol. Life Sci. 69(14), 2435-2442 (2012).
23. Arbiser JL, Fan CY, Su X et al. Involvement of p53 and p16 tumor suppressor genes in recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma. J. Invest. Dermatol. 123(4), 788-790 (2004).
24. Usatyuk PV, Fu P, Mohan V et al. Role of c-Met/phosphatidylinositol 3-kinase (PI3K)/Akt signaling in hepatocyte growth factor (HGF)-mediated lamellipodia formation, reactive oxygen species (ROS) generation, and motility of lung endothelial cells. J. Biol. Chem. 289(19), 13476-13491 (2014). • Comprehensive paper demonstrating the reactive oxygen-driven phenotype in endothelial cells, especially the close relationship of PI3K signaling with reactive oxgyen.
25. Pise-Masison CA, Radonovich M, Sakaguchi K, Appella E, Brady JN. Phosphorylation of p53: a novel pathway for p53 inactivation in human T-cell lymphotropic virus type 1-transformed cells. J. Virol. 72(8), 6348-6355 (1998).
26. Laurie NA, Donovan SL, Shih CS et al. Inactivation of the p53 pathway in retinoblastoma. Nature 444(7115), 61-66 (2006).
27. Garufi A, D'Orazi V, Arbiser JL, D'Orazi G. Gentian violet induces wtp53 transactivation in cancer cells. Int. J. Oncol. 44(4), 1084-1090 (2014). • Recent paper demonstrating that the commonly used dye gentian violet can reactivate wild-type p53 in tumor cells by reversing its oxidation. This provides proof of principle that NADPH oxidase inhibitors such as gentian violet can reactivate p53.
28. Mishra MV, Bisht KS, Sun L et al. DNMT1 as a molecular target in a multimodality-resistant phenotype in tumor cells. Mol. Cancer Res. 6(2), 243-249 (2008).
29. Kang KA, Zhang R, Kim GY, Bae SC, Hyun JW. Epigenetic changes induced by oxidative stress in colorectal cancer cells: methylation of tumor suppressor RUNX3. Tumour Biol. 33(2), 403-412 (2012).
30. Denicola GM, Karreth FA, Humpton TJ et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475(7354), 106-109 (2011). •• Demonstrates that high levels of reactive oxygen can promote oncogene-induced senescence and that antioxidants may thus promote early tumorigenesis by blocking oncogene-induced senescence.
31. Klangby U, Okan I, Magnusson KP, Wendland M, Lind P, Wiman KG. p16/INK4a and p15/INK4b gene methylation and absence of p16/INK4a mRNA and protein expression in Burkitt's lymphoma. Blood 91(5), 1680-1687 (1998).
32. Parker JF, Florell SR, Alexander A, Disario JA, Shami PJ, Leachman SA. Pancreatic carcinoma surveillance in patients with familial melanoma. Arch. Dermatol. 139(8), 1019-1025 (2003).
33. Kamb A, Shattuck-Eidens D, Eeles R et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat. Genet. 8(1), 23-26 (1994).
34. Fried L, Arbiser JL. The reactive oxygen-driven tumor: relevance to melanoma. Pigment Cell Melanoma Res. 21(2), 117-122 (2008).
35. Govindarajan B, Sligh JE, Vincent BJ et al. Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. J. Clin. Invest. 117(3), 719-729 (2007). •• First paper to demonstrate that Akt can promote tumorigenesis through the induction of NADPH oxidase or promoting survival in the presence of mitochondrial mutations.
36. Corazao-Rozas P, Guerreschi P, Jendoubi M et al. Mitochondrial oxidative stress is the Achille's heel of melanoma cells resistant to Braf-mutant inhibitor. Oncotarget 4(11), 1986-1998 (2013).
37. Villanueva J, Vultur A, Lee JT et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18(6), 683-695 (2010).
38. Arbiser JL, Bips M, Seidler A, Bonner MY, Kovach C. Combination therapy of imiquimod and gentian violet for cutaneous melanoma metastases. J. Am. Acad. Dermatol. 67(2), e81-83 (2012).
39. Jones RG, Saibil SD, Pun JM et al. NF-kappaB couples protein kinase B/Akt signaling to distinct survival pathways and the regulation of lymphocyte homeostasis in vivo. J. Immunol. 175(6), 3790-3799 (2005).
40. Yu Y, Varughese J, Brown LF, Mulliken JB, Bischoff J. Increased Tie2 expression, enhanced response to angiopoietin-1, and dysregulated angiopoietin-2 expression in hemangioma-derived endothelial cells. Am. J. Pathol. 159(6), 2271-2280 (2001).
41. Cerimele F, Brown LF, Bravo F, Ihler GM, Kouadio P, Arbiser JL. Infectious angiogenesis: Bartonella bacilliformis infection results in endothelial production of angiopoetin-2 and epidermal production of vascular endothelial growth factor. Am. J. Pathol. 163(4), 1321-1327 (2003).
42. Perry BN, Govindarajan B, Bhandarkar SS et al. Pharmacologic blockade of angiopoietin-2 is efficacious against model hemangiomas in mice. J. Invest. Dermatol. 126(10), 2316-2322 (2006).
43. Lapidoth M, Ben-Amitai D, Bhandarkar S, Fried L, Arbiser JL. Efficacy of topical application of eosin for ulcerated hemangiomas. J. Am. Acad. Dermatol. 60(2), 350-351 (2009).
44. Lawley LP, Cerimele F, Weiss SW et al. Expression of Wilms tumor 1 gene distinguishes vascular malformations from proliferative endothelial lesions. Arch. Dermatol. 141(10), 1297-1300 (2005).
45. Zamora-Avila DE, Franco-Molina MA, Trejo-Avila LM, Rodriguez-Padilla C, Resendez-Perez D, Zapata-Benavides P. RNAi silencing of the WT1 gene inhibits cell proliferation and induces apoptosis in the B16F10 murine melanoma cell line. Melanoma Res. 17(6), 341-348 (2007).
46. Bhandarkar SS, Jaconi M, Fried LE et al. Fulvene-5 potently inhibits NADPH oxidase 4 and blocks the growth of endothelial tumors in mice. J. Clin. Invest. 119(8), 2359-2365 (2009).
47. Sjolund J, Johansson M, Manna S et al. Suppression of renal cell carcinoma growth by inhibition of Notch signaling in vitro and in vivo. J. Clin. Invest. 118(1), 217-228 (2008).
48. Proweller A, Tu L, Lepore JJ et al. Impaired notch signaling promotes de novo squamous cell carcinoma formation. Cancer Res. 66(15), 7438-7444 (2006).
49. Egloff AM, Grandis J R. Molecular pathways: context-dependent approaches to Notch targeting as cancer therapy. Clin. Cancer Res. 18(19), 5188-5195 (2012).
50. Warburg O. On respiratory impairment in cancer cells. Science 124(3215), 269-270 (1956).
51. Cuezva JM, Krajewska M, De Heredia ML et al. The bioenergetic signature of cancer: a marker of tumor progression. Cancer Res. 62(22), 6674-6681 (2002).
52. Formentini L, Sanchez-Arago M, Sanchez-Cenizo L, Cuezva JM. The mitochondrial ATPase inhibitory factor 1 triggers a ROS-mediated retrograde prosurvival and proliferative response. Mol. Cell 45(6), 731-742 (2012).
53. Boivin B, Zhang S, Arbiser JL, Zhang ZY, Tonks NK. A modified cysteinyl-labeling assay reveals reversible oxidation of protein tyrosine phosphatases in angiomyolipoma cells. Proc. Natl Acad. Sci. USA 105(29), 9959-9964 (2008).
54. Munson JM, Fried L, Rowson SA et al. Anti-invasive adjuvant therapy with imipramine blue enhances chemotherapeutic efficacy against glioma. Sci. Transl. Med. 4(127), 127ra136 (2012). •• Example of the potential of sequential therapy and NADPH oxidase inhibitors to act as adjuvants with existing chemotheraputics (in this case doxorubicin) and markedly extend the length of survival when treating gliomas in vivo.
55. Parsa AT, Waldron JS, Panner A et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat. Med. 13(1), 84-88 (2007).
56. Crane C, Panner A, Pieper RO, Arbiser J, Parsa AT. Honokiol-mediated inhibition of PI3K/mTOR pathway: a potential strategy to overcome immunoresistance in glioma, breast, and prostate carcinoma without impacting T cell function. J. Immunother. 32(6), 585-592 (2009).
57. Gabrilovich DI, Chen HL, Girgis KR et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2(10), 1096-1103 (1996).
58. Oyama T, Ran S, Ishida T et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J. Immunol. 160(3), 1224-1232 (1998).
59. Meyer C, Sevko A, Ramacher M et al. Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proc. Natl Acad. Sci. USA 108(41), 17111-17116 (2011).
60. Fried LE, Arbiser J L. Honokiol, a multifunctional antiangiogenic and antitumor agent. Antioxid. Redox Signal. 11(5), 1139-1148 (2009).
61. Bai X, Cerimele F, Ushio-Fukai M et al. Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo. J. Biol. Chem. 278(37), 35501-35507 (2003).
62. Battle TE, Arbiser J, Frank DA. The natural product honokiol induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells. Blood 106(2), 690-697 (2005).
63. Ishikawa C, Arbiser JL, Mori N. Honokiol induces cell cycle arrest and apoptosis via inhibition of survival signals in adult T-cell leukemia. Biochim. Biophys. Acta 1820(7), 879-887 (2012).
64. Shigemura K, Arbiser JL, Sun SY et al. Honokiol, a natural plant product, inhibits the bone metastatic growth of human prostate cancer cells. Cancer 109(7), 1279-1289 (2007).
65. Nagalingam A, Arbiser JL, Bonner MY, Saxena NK, Sharma D. Honokiol activates AMP-activated protein kinase in breast cancer cells via an LKB1-dependent pathway and inhibits breast carcinogenesis. Breast Cancer Res. 14(1), R35 (2012).
66. Garrido-Urbani S, Jemelin S, Deffert C et al. Targeting vascular NADPH oxidase 1 blocks tumor angiogenesis through a PPARalpha mediated mechanism. PLoS ONE 6(2), e14665 (2011).
67. Planavila A, Iglesias R, Giralt M, Villarroya F. Sirt1 acts in association with PPARalpha to protect the heart from hypertrophy, metabolic dysregulation, and inflammation. Cardiovasc. Res. 90(2), 276-284 (2011).
68. Kauppinen A, Suuronen T, Ojala J, Kaarniranta K, Salminen A. Antagonistic crosstalk between NF-kappaB and SIRT1 in the regulation of inflammation and metabolic disorders. Cell Signal. 25(10), 1939-1948 (2013).
69. Salminen A, Ojala J, Kaarniranta K, Haapasalo A, Hiltunen M, Soininen H. Astrocytes in the aging brain express characteristics of senescence-associated secretory phenotype. Eur. J. Neurosci. 34(1), 3-11 (2011).
70. Kihlstrom M, Ojala J, Salminen A. Decreased level of cardiac antioxidants in endurance-trained rats. Acta Physiol. Scand. 135(4), 549-554 (1989).
71. Carroll KC, Viollet B, Suttles J. AMPKalpha1 deficiency amplifies proinflammatory myeloid APC activity and CD40 signaling. J. Leukoc. Biol. 94(6), 1113-1121 (2013).
72. Park SJ, Lee KS, Kim SR et al. AMPK activation reduces vascular permeability and airway inflammation by regulating HIF/VEGFA pathway in a murine model of toluene diisocyanate-induced asthma. Inflamm. Res. 61(10), 1069-1083 (2012).
73. Carnesecchi S, Deffert C, Donati Y et al. A key role for NOX4 in epithelial cell death during development of lung fibrosis. Antioxid. Redox Signal. 15(3), 607-619 (2011).
74. Deng J, Qian Y, Geng L et al. Involvement of p38 mitogen-activated protein kinase pathway in honokiol-induced apoptosis in a human hepatoma cell line (hepG2). Liver Int. 28(10), 1458-1464 (2008).
75. Lee B, Kim CH, Moon S K. Honokiol causes the p21WAF1-mediated G(1)-phase arrest of the cell cycle through inducing p38 mitogen activated protein kinase in vascular smooth muscle cells. FEBS Lett. 580(22), 5177-5184 (2006)